Social networks
7,709Activities
Technologies
Entity types
Location
Gaston Geenslaan 1, 3001 Leuven, Belgium
Leuven
Belgium
Employees
Scale: 51-200
Estimated: 40
Engaged corporates
0Added in Motherbase
1 year agoAdvancing Science. Enhancing Vision
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME.
THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy.
Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.
Oxurion dedicated to developing innovative treatments to improve and better preserve vision for patients with diabetic macular edema (DME)